Compare COMBAT DRUGS with CAPLIN POINT - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

COMBAT DRUGS vs CAPLIN POINT - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    COMBAT DRUGS CAPLIN POINT COMBAT DRUGS/
CAPLIN POINT
 
P/E (TTM) x 24.5 20.6 119.2% View Chart
P/BV x 3.7 5.0 74.4% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 COMBAT DRUGS   CAPLIN POINT
EQUITY SHARE DATA
    COMBAT DRUGS
Mar-20
CAPLIN POINT
Mar-21
COMBAT DRUGS/
CAPLIN POINT
5-Yr Chart
Click to enlarge
High Rs34686 5.0%   
Low Rs16264 6.1%   
Sales per share (Unadj.) Rs23.7140.3 16.9%  
Earnings per share (Unadj.) Rs1.133.2 3.3%  
Cash flow per share (Unadj.) Rs1.638.1 4.3%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Avg Dividend yield %00.6 0.0%  
Book value per share (Unadj.) Rs12.4154.8 8.0%  
Shares outstanding (eoy) m10.1075.64 13.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.13.4 31.3%   
Avg P/E ratio x23.114.3 161.6%  
P/CF ratio (eoy) x15.312.5 123.2%  
Price / Book Value ratio x2.03.1 66.0%  
Dividend payout %09.0 0.0%   
Avg Mkt Cap Rs m25435,930 0.7%   
No. of employees `000NANA-   
Total wages/salary Rs m1961,020 19.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m24010,613 2.3%  
Other income Rs m3235 1.2%   
Total revenues Rs m24310,848 2.2%   
Gross profit Rs m253,286 0.8%  
Depreciation Rs m6370 1.5%   
Interest Rs m816 48.6%   
Profit before tax Rs m153,136 0.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4622 0.6%   
Profit after tax Rs m112,514 0.4%  
Gross profit margin %10.531.0 34.0%  
Effective tax rate %24.919.8 125.6%   
Net profit margin %4.623.7 19.4%  
BALANCE SHEET DATA
Current assets Rs m24410,358 2.4%   
Current liabilities Rs m2301,429 16.1%   
Net working cap to sales %5.684.1 6.6%  
Current ratio x1.17.3 14.6%  
Inventory Days Days1177 1,776.8%  
Debtors Days Days222961 23.2%  
Net fixed assets Rs m1273,278 3.9%   
Share capital Rs m101897 11.3%   
"Free" reserves Rs m2510,813 0.2%   
Net worth Rs m12611,710 1.1%   
Long term debt Rs m00-   
Total assets Rs m37013,636 2.7%  
Interest coverage x2.9198.2 1.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.60.8 83.3%   
Return on assets %5.118.6 27.3%  
Return on equity %8.821.5 40.8%  
Return on capital %17.826.9 66.2%  
Exports to sales %044.4 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA4,713 0.0%   
Imports (cif) Rs mNA333 0.0%   
Fx inflow Rs m04,713 0.0%   
Fx outflow Rs m0333 0.0%   
Net fx Rs m04,379 0.0%   
CASH FLOW
From Operations Rs m-1522,658 -5.7%  
From Investments Rs m-1-54 2.3%  
From Financial Activity Rs m180-240 -75.2%  
Net Cashflow Rs m282,362 1.2%  

Share Holding

Indian Promoters % 0.0 69.0 -  
Foreign collaborators % 45.9 0.0 -  
Indian inst/Mut Fund % 0.0 3.0 -  
FIIs % 0.0 1.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 54.1 31.0 174.6%  
Shareholders   12,796 83,462 15.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare COMBAT DRUGS With:   ADVANCED ENZYME TECHNOLOGIES  NEULAND LABS  HESTER BIOSCIENCES  SAMRAT PHARMA  PIRAMAL ENTERPRISES  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Slumped 1,688 Points Today(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended deep in the red.

Related Views on News

CAPLIN POINT 2020-21 Annual Report Analysis (Annual Result Update)

Oct 18, 2021 | Updated on Oct 18, 2021

Here's an analysis of the annual report of CAPLIN POINT for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of CAPLIN POINT. Also includes updates on the valuation of CAPLIN POINT.

CAPLIN POINT Announces Quarterly Results (1QFY22); Net Profit Up 31.1% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, CAPLIN POINT has posted a net profit of Rs 715 m (up 31.1% YoY). Sales on the other hand came in at Rs 3 bn (up 25.1% YoY). Read on for a complete analysis of CAPLIN POINT's quarterly results.

CAPLIN POINT Announces Quarterly Results (4QFY21); Net Profit Up 39.0% (Quarterly Result Update)

Jul 9, 2021 | Updated on Jul 9, 2021

For the quarter ended March 2021, CAPLIN POINT has posted a net profit of Rs 679 m (up 39.0% YoY). Sales on the other hand came in at Rs 3 bn (up 29.5% YoY). Read on for a complete analysis of CAPLIN POINT's quarterly results.

More Views on News

Most Popular

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

How to Hit Rs 100 Crore Wealth in Your Lifetime(Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

COMBAT DRUGS SHARE PRICE


Nov 26, 2021 (Close)

TRACK COMBAT DRUGS

  • Track your investment in COMBAT DRUGS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMBAT DRUGS 5-YR ANALYSIS

COMPARE COMBAT DRUGS WITH

MARKET STATS